Mefloquine is not recommended for severe malaria infections, particularly infections from "P. falciparum", which should be treated with intravenous antimalarials. Mefloquine does not eliminate parasites in the liver phase of the disease, and people with "P. vivax" malaria should be treated with a second drug that is effective for the liver phase, such as primaquine. Mefloquine is widely used for the treatment of malaria in pregnancy. Limited data suggests that it is safe for this purpose. Resistance to mefloquine is now common around the west border in Cambodia and other parts of Southeast Asia. The mechanism of resistance is by increase
Drugs for Neglected Diseases Initiative in 32 African countries, in India, Ecuador and in Colombia, and included in the WHO Model List of Essential Medicines. More than 437 million treatments had been distributed. A technology transfer agreement has been signed with industrial partner Zenufa in Tanzania in order to provide an additional source of ASAQ. ASAQ was handed over to the MMV Access and Product Management Team in May 2015. The second antimalarial treatment developed by DND"i" is a fixed-dose combination of artesunate and mefloquine launched in 2008. It was developed by an international collaboration within the FACT Project Consortium. It has a simple and